Aburto Myriam, Rodríguez-Portal José Antonio, Fernandez-Fabrellas Estrella, García Sevila Raquel, Herrera Lara Susana, Bollo de Miguel Elena, González Ruiz José María, Molina-Molina María, Safont Muñoz Belén, Godoy Mayoral Raul, Romero Ortiz Ana Dolores, Soler Sempere María José, Castillo Villegas Diego, Gaudó Navarro Javier, Tomás López Laura, Nuñez Sanchez Belén, Palacios Hidalgo Zulema, Sellares Torres Jacobo, Sacristán Bou Lirios, Nieto Barbero María Asunción, Casanova Espinosa Alvaro, Portillo-Carroz Karina, Cano-Jimenez Esteban, Acosta Fernández Orlando, Legarreta María José, Valenzuela Claudia
Servicio de Neumología, Hospital Universitario Galdakao-Usansolo, Galdakao, Bizkaia, España.
Departamento de Medicina, Universidad del País Vasco- Euskal Herriko Unibertsitatea, País Vasco, España.
Open Respir Arch. 2024 May 15;6(3):100334. doi: 10.1016/j.opresp.2024.100334. eCollection 2024 Jul-Sep.
The objective of the study was to analyze the diagnostic process and the time until the start of treatment of patients with idiopathic pulmonary fibrosis in relation to the publication of successive clinical practice guide.
Multicenter, observational, ambispective study, in which patients includes in the idiopathic pulmonary fibrosis registry of the Spanish Society of Pulmonologist and Thoracic Surgery were analyzed. An electronic data collection notebook was enabled on the society's website. Sociodemographic and clinical variables were collected at diagnosis and follow-up of the patients.
From January 2012 to december 2019, 1064 patients were included in the registry, with 929 finally analyzed. The diagnosis process varied depending on the year in which it was performed, and the radiological pattern observed in the high-resolution computed tomography. Up to 26.3% of the cases (244) were diagnosed with chest high-resolution computed tomography and clinical evaluation. Surgical biopsy was used up to 50.2% of cases diagnosed before 2011, while it has been used in 14.2% since 2018. The median time from the onset of symptoms to diagnosis was 360 days (IQR 120-720), taking more than 2 years in the 21.0% of patients. A percentage of 79.4 of patients received antifibrotic treatment. The average time from diagnosis to the antifibrotic treatment has been 309 ± 596.5 days, with a median of 49 (IQR 0-307).
The diagnostic process, including the time until diagnosis and the type of test used, has changed from 2011 to 2019, probably due to advances in clinical research and the publication of diagnostic-therapeutic consensus guidelines.
本研究的目的是分析特发性肺纤维化患者的诊断过程以及开始治疗前的时间,并与连续临床实践指南的发布情况相关联。
多中心、观察性、双向性研究,分析纳入西班牙肺科和胸外科医师协会特发性肺纤维化登记处的患者。在协会网站上启用了电子数据收集笔记本。在患者诊断和随访时收集社会人口统计学和临床变量。
2012年1月至2019年12月,登记处纳入1064例患者,最终分析929例。诊断过程因进行诊断的年份以及高分辨率计算机断层扫描中观察到的放射学模式而异。高达26.3%的病例(244例)通过胸部高分辨率计算机断层扫描和临床评估确诊。2011年之前诊断的病例中,高达50.2%使用了外科活检,而自2018年以来这一比例为14.2%。从症状出现到诊断的中位时间为360天(四分位间距120 - 720天),21.0%的患者诊断时间超过2年。79.4%的患者接受了抗纤维化治疗。从诊断到抗纤维化治疗的平均时间为309±596.5天,中位时间为49天(四分位间距0 - 307天)。
从2011年到2019年,诊断过程,包括诊断前的时间和所使用的检测类型发生了变化,这可能归因于临床研究的进展以及诊断治疗共识指南的发布。